The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment. The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline. As a result, Moderna could launch other potential blockbusters over the next few years.
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.